XTL Biopharmaceuticals Statistics
Total Valuation
XTLB has a market cap or net worth of $15.63 million. The enterprise value is $13.83 million.
| Market Cap | 15.63M |
| Enterprise Value | 13.83M |
Important Dates
The next estimated earnings date is Friday, February 21, 2025, before market open.
| Earnings Date | Feb 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
XTLB has 881.39 million shares outstanding. The number of shares has increased by 7.97% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 881.39M |
| Shares Change (YoY) | +7.97% |
| Shares Change (QoQ) | +31.89% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 749.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 300.66 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.81
| Current Ratio | 0.81 |
| Quick Ratio | 0.75 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -42.16 |
Financial Efficiency
Return on equity (ROE) is -25.70% and return on invested capital (ROIC) is -23.73%.
| Return on Equity (ROE) | -25.70% |
| Return on Assets (ROA) | -16.33% |
| Return on Capital (ROIC) | -23.73% |
| Revenue Per Employee | $6,571 |
| Profits Per Employee | -$150,857 |
| Employee Count | 7 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +100.00% in the last 52 weeks. The beta is 1.00, so XTLB's price volatility has been similar to the market average.
| Beta (5Y) | 1.00 |
| 52-Week Price Change | +100.00% |
| 50-Day Moving Average | 1.83 |
| 200-Day Moving Average | 2.31 |
| Relative Strength Index (RSI) | 43.10 |
| Average Volume (20 Days) | 13,856 |
Short Selling Information
| Short Interest | 92,137 |
| Short Previous Month | 70,822 |
| Short % of Shares Out | 1.02% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.40 |
Income Statement
In the last 12 months, XTLB had revenue of $46,000 and -$1.06 million in losses. Loss per share was -$0.00.
| Revenue | 46,000 |
| Gross Profit | 46,000 |
| Operating Income | -1.56M |
| Pretax Income | -1.78M |
| Net Income | -1.06M |
| EBITDA | n/a |
| EBIT | -1.56M |
| Loss Per Share | -$0.00 |
Balance Sheet
| Cash & Cash Equivalents | 1.72M |
| Total Debt | n/a |
| Net Cash | 1.72M |
| Net Cash Per Share | $0.00 |
| Equity (Book Value) | 5.72M |
| Book Value Per Share | 0.01 |
| Working Capital | -480,000 |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -3,391.30% |
| Pretax Margin | -2,295.65% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
XTLB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.97% |
| Shareholder Yield | -7.97% |
| Earnings Yield | -6.76% |
| FCF Yield | n/a |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on February 10, 2017. It was a reverse split with a ratio of 0.2:1.
| Last Split Date | Feb 10, 2017 |
| Split Type | Reverse |
| Split Ratio | 0.2:1 |
Scores
XTLB has an Altman Z-Score of -22.47. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -22.47 |
| Piotroski F-Score | n/a |